Direct cellular reprogramming for cardiac repair and regeneration

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Cardiac Biology

Background:

• Heart failure leads to significant morbidity and mortality due to cardiomyocyte loss and impaired cardiac function.
• Current treatments for heart failure do not effectively reverse myocardial damage, necessitating novel regenerative strategies.
• Cardiac fibroblasts are implicated in pathological cardiac remodeling, presenting a potential target for reprogramming.

Purpose of the Study:

• To review the current status of in situ reprogramming strategies for cardiac repair.
• To explore the potential of reprogramming endogenous cardiac fibroblasts into functional cardiomyocytes.
• To discuss future perspectives for clinical translation of cardiac reprogramming therapies.

Main Methods:

• Review of existing literature on fibroblast reprogramming using transcription factors, microRNAs, and small molecules.
• Analysis of studies demonstrating in vitro and in vivo reprogramming in murine and human fibroblast models.
• Evaluation of functional outcomes and cardiomyocyte-like characteristics of reprogrammed cells.

Main Results:

• Successful reprogramming of fibroblasts into cardiomyocyte-like cells has been achieved in preclinical models.
• Reprogrammed cells exhibit characteristic cardiomyocyte morphology, gene expression, and spontaneous contraction.
• Cardiac function improvement in post-infarct models has been observed following fibroblast reprogramming.

Conclusions:

• In situ reprogramming of cardiac fibroblasts offers a promising alternative to cell delivery for cardiac regeneration.
• While successful in preclinical studies, significant barriers to therapeutic reprogramming in humans remain.
• Further research is crucial to overcome these challenges and advance cardiac reprogramming towards clinical application.